Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia

B-cell receptor signalling inhibition by targeting Bruton tyrosine kinase (BTK) is effective in treating chronic lymphocytic leukemia (CLL). The BTK inhibitor ibrutinib may be intolerable for some patients. Acalabrutinib is a more selective BTK inhibitor that may be better tolerated by patients who...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Kerry A. Rogers, Philip A. Thompson, John N. Allan, Morton Coleman, Jeff P. Sharman, Bruce D. Cheson, Daniel Jones, Raquel Izumi, Melanie M. Frigault, Cheng Quah, Rakesh K. Raman, Priti Patel, Min Hui Wang, Thomas J. Kipps
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Ferrata Storti Foundation 2021-03-01
coleção:	Haematologica
Acesso em linha:	https://haematologica.org/article/view/10212
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!